Kurs
+37,44%
Likviditet
5,89 MSEK
Kalender
| Est. tid* | ||
| 2026-02-20 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-14 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-30 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2025-06-27 | - | Årsstämma |
| 2025-05-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-21 | - | Extra Bolagsstämma 2024 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Årsstämma |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-17 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2024-04-25 | - | Split CLS B 200:1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-29 | - | Årsstämma |
| 2023-06-22 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2023-06-08 | - | Extra Bolagsstämma 2023 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Extra Bolagsstämma 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-29 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2022-06-28 | - | Årsstämma |
| 2022-05-19 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-29 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2021-06-28 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-31 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2019-05-17 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-18 | - | Extra Bolagsstämma 2019 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-20 | - | Årsstämma |
| 2018-06-14 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-18 | - | Extra Bolagsstämma 2018 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-28 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2017-06-27 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-01-31 | - | Bokslutskommuniké 2016 |
| 2017-01-20 | - | Extra Bolagsstämma 2017 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-18 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-16 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-21 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2015-06-11 | - | Årsstämma |
| 2015-05-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-23 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-20 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-18 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2014-06-17 | - | Årsstämma |
| 2014-05-22 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | - | Bokslutskommuniké 2013 |
| 2013-11-22 | - | Kvartalsrapport 2013-Q3 |
| 2013-09-19 | - | Extra Bolagsstämma 2013 |
| 2013-08-20 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-10 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2013-06-07 | - | Årsstämma |
| 2013-05-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-25 | - | Bokslutskommuniké 2012 |
| 2012-11-23 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-08 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2012-06-07 | - | Årsstämma |
| 2012-04-20 | - | Kvartalsrapport 2012-Q1 |
| 2012-01-09 | - | Bokslutskommuniké 2011 |
| 2012-01-04 | - | Extra Bolagsstämma 2012 |
| 2011-11-21 | - | Kvartalsrapport 2011-Q3 |
| 2011-09-26 | - | Kapitalmarknadsdag 2010 |
| 2011-08-22 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-10 | - | Årsstämma |
| 2011-05-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-24 | - | Bokslutskommuniké 2010 |
| 2010-11-24 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-25 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-28 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2010-05-26 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-26 | - | Bokslutskommuniké 2009 |
| 2009-11-30 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sweden - September 4th, 2025 - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for expansion of the labeling of ClearPoint Prism® Neuro Laser Therapy System.
In addition to the existing clearance for use with 3.0 Tesla (3.0T) magnetic resonance imaging (MRI) guidance, the system is now also cleared for use with 1.5T MRI guidance.
The expanded clearance significantly broadens the accessibility of the Prism Neuro Laser Therapy System for U.S. hospitals and patients, as approximately half of all MRI-guided neurosurgical procedures are performed using 1.5T scanners. The approval thereby more than doubles* the addressable U.S. market for Neuro Laser Interstitial Thermal Therapy (Neuro LITT) procedures.
"This FDA clearance is a pivotal milestone for CLS and our partner Clearpoint Neuro. By expanding compatibility to 1.5T MR scanners, we are unlocking access to minimally invasive laser ablation therapy for a much larger number of patients and hospitals across the U.S. This is a major step in our mission to enable broader adoption of Neuro LITT procedures and to support physicians with safe, effective, and image-guided solutions for treating patients with severe neurological conditions", commented Dan J. Mogren, CEO of CLS.
The ClearPoint Prism® Neuro Laser Therapy System is marketed and sold in the U.S. exclusively by Clearpoint Neuro, Inc., under the companies' global partnership agreement. The expanded labeling is expected to accelerate adoption and clinical use of Neuro LITT procedures, enabling hospitals with both 3T and 1.5T MRI scanners to treat a larger range of patients.
*Moser E, Laistler E, Schmitt F and Kontaxis G (2017) Ultra-High Field NMR and MRI-The Role of Magnet Technology to Increase Sensitivity and Specificity. Front Phys. 5:33. doi: 10.3389/fphy.2017.00033.
For more Information please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-post: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-09-2025 17:01 CET.